Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 26, 2004

View Archived Issues

AEOL-10150 attenuates spinal cord compression injury in mice

Vasogen continues to make good progress during second quarter

Tumor-selective expression of cytotoxic adenovirus

Metformin combined with DPP-IV inhibitor shows promise in treating type 2 diabetes

Medarex reaches SPA agreement for phase III trial of MDX-010

Promise for PARP-1 inhibitor in Parkinson's disease

Broad potential for TC-1734 in memory and learning disorders

Sumatriptan shows efficacy in migraine-like pain, but not in other pain models

VEGFR2-targeted peptides and their use in cancer diagnosis and treatment

Three series of alphavbeta3/alphavbeta5 integrin antagonists reported by Pfizer

AstraZeneca team identifies novel Tie-2 kinase inhibitors

New CXCR1-derived peptides and their use as IL-8 antagonists

Saratin shows antithrombotic effects in human atherosclerotic plaques

Pfizer presents new MK2 inhibitors and their use

Pfizer scientists design novel P2X7 antagonists

DAR-0100 to be studied for working memory deficits in schizophrenia

CuraGen collaborates with NCI on PXD-101 development

Orphan drug designations for forodesine

HGS-TR2J enters clinical development

Roche seeks new indication for Xeloda in U.S., E.U.

Gene variant data analysis results for Miraxion in Huntington's disease

SGN-40 receives orphan drug designation for multiple myeloma

Positive phase III data for Neurodex for PBA in MS patients

AVI BioPharma enters dengue virus CRADA with CDC

Sterix presents new dual aromatase/steroid sulfatase inhibitor

PPARpan agonist shows promise for type 2 diabetes and metabolic syndrome

Discovery of Bay-59-7939 discussed at ACS meeting

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for April 21, 2026
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
At AACR: Epigenetic fingerprints in metastases track tumor origin
BioWorld
When a tumor migrates and colonizes another tissue or organ, it can be identified as a metastasis, but its origin is not always clear. Now, a study based on...